

Presbyopia - Pipeline Insight, 2021

<https://marketpublishers.com/r/P93304CBAD66EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P93304CBAD66EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Presbyopia - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Presbyopia Understanding

Presbyopia: Overview

Presbyopia is the gradual loss of eyes' ability to focus on nearby objects. It's a natural part of aging. Common symptoms of presbyopia are eyestrain or headaches after reading or doing close work, difficulty reading small print, fatigue from doing close work, overall problems seeing and focusing on objects that are close, or squinting. Presbyopia is diagnosed by a basic eye exam, which includes a refraction assessment and an eye health exam. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects. Treatment options include wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia.

'Presbyopia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Presbyopia pipeline landscape is provided which includes the disease overview and Presbyopia treatment guidelines. The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve Presbyopia.

Presbyopia Emerging Drugs Chapters

This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Presbyopia Emerging Drugs

AGN-190584: AbbVie

AGN-190584 is an investigational, novel optimized formulation of pilocarpine specifically designed for the treatment of presbyopia as a topical, once-daily drop delivered by a proprietary vehicle. The primary mechanism of action is through pupil constriction to enhance depth of focus and improve near and intermediate vision while maintaining pupillary response to different lighting conditions – an effect known as dynamic pupil modulation. The drug is in Preregistration for the treatment of Presbyopia.

BRIMOCHOL: Visus Therapeutics

BRIMOCHOL is a proprietary pupil-modulating eye drop that combines two well-studied, FDA-approved pharmaceuticals: carbachol (a cholinergic agent) and brimonidine tartrate (an alpha-2 agonist). Together, they produce a “pinhole effect,” which reduces the size of the pupil so that only centrally focused light rays are able to enter the eye, thereby sharpening distant and near images while minimizing side effects. The drug is in Phase II clinical studies for the treatment of Presbyopia.

Further product details are provided in the report.....

Presbyopia: Therapeutic Assessment

This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Presbyopia

There are approx. 10+ key companies which are developing the therapies for Presbyopia. The companies which have their Presbyopia drug candidates in the most advanced stage, i.e. Preregistration include, AbbVie.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Presbyopia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key

players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.

Presbyopia Report Insights

Presbyopia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Presbyopia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Presbyopia drugs?

How many Presbyopia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Presbyopia?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Presbyopia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AbbVie

Orasis Pharmaceuticals

Eyenovia

Aclaris Therapeutics

Ocuphire Pharma

Visus Therapeutics

Ocularis Pharma

Cellix Bio

Key Products

AGN-190584

AGN-241622

CSF-1

ARVN-003

Oxymetazoline

Phentolamine/pilocarpine

BRIMOCHOL

Phentolamine

CLX-OPH-561

Contents

- Introduction
- Executive Summary
- Presbyopia: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Presbyopia – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- CSF-1: Orasis Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- BRIMOCHOL: Visus Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Early Stage Products (Phase I/II)
 - Comparative Analysis
- AGN-241622: AbbVie
 - Product Description
 - Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
CLX-OPH-561: Cellix Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Presbyopia Key Companies
Presbyopia Key Products
Presbyopia- Unmet Needs
Presbyopia- Market Drivers and Barriers
Presbyopia- Future Perspectives and Conclusion
Presbyopia Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Presbyopia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Presbyopia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Presbyopia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P93304CBAD66EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P93304CBAD66EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970